10-K: Voyager Acquisition Corp. Details Security Structure in 10-K Filing

Voyager Acquisition Corp.'s 10-K filing outlines the company's share structure, warrant details, and governance policies as of December 31, 2024.

Summary

• Voyager Acquisition Corp., a Cayman Islands exempted company, filed its annual report on Form 10-K as of December 31, 2024.
• The company has three classes of securities registered under Section 12 of the Securities Exchange Act of 1934: Class A ordinary shares, warrants, and units.
• As of March 31, 2025, there were 25,300,000 Class A ordinary shares outstanding.
• Each unit consists of one Class A ordinary share and one-half of one redeemable public warrant.
• Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, exercisable 30 days after the completion of the initial business combination and expiring five years after completion or earlier upon redemption or liquidation.
• The company is authorized to issue 200,000,000 Class A ordinary shares, 20,000,000 Class B ordinary shares, and 1,000,000 preference shares, all with a par value of US$0.0001 each.
• Ordinary shareholders are entitled to one vote per share, with Class A and Class B shares voting together as a single class, except as required by law.
• The company's board of directors is divided into three classes, each generally serving a three-year term.
• Public shareholders have the opportunity to redeem their public shares upon completion of the initial business combination at a per-share price equal to the aggregate amount in the trust account, initially anticipated to be $10.05 per public share.
• Initial shareholders have agreed to waive their redemption rights with respect to founder shares and public shares they hold.
• If the company cannot complete an initial business combination within the completion window, it will redeem public shares at a per-share price equal to the amount in the trust account.
• Founder shares are subject to transfer restrictions and will automatically convert into Class A ordinary shares upon consummation of the initial business combination.
• The company's board of directors can issue preference shares without shareholder approval, which could affect the voting power of ordinary shareholders and have anti-takeover effects.
• The company may redeem warrants for cash at $0.01 per warrant if the closing price of the ordinary shares equals or exceeds $18.00 per share.
• Up to $1,500,000 of working capital loans from the sponsor may be convertible into private placement-equivalent warrants at $1.00 per warrant.
• The company has not paid any cash dividends on its ordinary shares to date and does not intend to prior to the completion of a business combination.
• As of December 31, 2024, the aggregate market value of the Registrant's voting and non-voting common equity held by non-affiliates was approximately $256 million.

Sentiment

Score: 6

Explanation: The document is neutral in tone, providing factual information about the company's structure and operations. There are both positive aspects (redemption rights, experienced management) and risks (dependence on a single business, potential conflicts of interest), resulting in a balanced sentiment score.

Positives

• Public shareholders have a redemption option at approximately $10.05 per share, providing a safety net.
• The management team has experience across diverse domains, including the healthcare sector, financial services, capital markets, special purpose acquisition companies, mergers and acquisitions, private equity, and leadership roles in publicly traded firms.
• Flexibility in structuring the initial business combination using cash, debt, or equity securities.

Negatives

• If the company fails to complete a business combination, warrants will expire worthless.
• The company's success depends entirely on a single business after the initial business combination, lacking diversification.
• The board's ability to issue preference shares without shareholder approval could have anti-takeover effects.
• The low price that the sponsor and/or executive officers and directors paid for the founder shares creates an incentive whereby our officers and directors could potentially make a substantial profit even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders.

Risks

• The company's prospects depend entirely on the future performance of a single business after the initial business combination.
• The assessment of the target business's management may not prove to be correct.
• Shareholders may not have the ability to approve the initial business combination.
• Claims against the trust account could reduce the per-share redemption amount.
• Competition from other entities seeking business combinations.
• The company is dependent on digital technologies of third parties, and any sophisticated and deliberate attacks on, or security breaches in, systems or infrastructure or the cloud that we utilize, including those of third parties, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential data.

Future Outlook

The company intends to complete an initial business combination, but there is no assurance that it will be successful. If a business combination is not completed within the specified time frame, the company will liquidate.

Industry Context

This announcement is typical for special purpose acquisition companies (SPACs) as they provide updates on their financial structure and progress towards identifying a target for a business combination. The focus on the healthcare industry aligns with current market trends and investor interest in the sector.

Comparison to Industry Standards

• The structure of Voyager Acquisition Corp. is typical of SPACs, with units consisting of shares and warrants.
• The redemption rights offered to public shareholders are standard practice in SPACs to provide downside protection.
• The management team's focus on the healthcare industry is a common strategy for SPACs seeking to leverage industry expertise.
• Comparable companies include other healthcare-focused SPACs such as CM Life Sciences III Inc. and DHC Acquisition Corp., which have similar structures and objectives.

Corporate Governance

Legal Proceedings

• As of December 31, 2024, there were no material litigation, arbitration, or governmental proceedings pending against the company or its management team.

Related Party Transactions

• The company has entered into an agreement to pay an affiliate of the sponsor $10,000 per month for office space and administrative support.
• The company has entered into an agreement to pay an affiliate of the sponsor $15,000 per month for consulting services of an entity affiliated to our Chief Executive Officer.
• Up to $1,500,000 of working capital loans from the sponsor may be convertible into private placement-equivalent warrants at $1.00 per warrant.

Stakeholder Impact

• Shareholders have the opportunity to redeem their shares upon completion of the initial business combination.
• The company's success depends on identifying and acquiring a suitable target business.
• The company's management team has a fiduciary duty to act in the best interests of the company and its shareholders.

Next Steps

• The company will continue to seek a target business for an initial business combination.
• The company will evaluate potential business combination targets and conduct due diligence.
• The company will provide shareholders with the opportunity to redeem their shares upon completion of the initial business combination.

Key Dates

Keywords

SPAC, initial business combination, Class A ordinary shares, warrants, units, redemption rights, founder shares, trust account, preference shares, private placement warrants, Cayman Islands, healthcare